Select publications

Crawford ED. Early versus late hormonal therapy: Debating the issues. Urology 2003;61(2 Suppl 1):8- 13. Abstract

Damber JE. Decreasing mortality rates for prostate cancer: Possible role of hormonal therapy? BJU Int 2004;93(6):695-701. Abstract

International Study of Infarct Survival Collaborative Group. Randomised trials of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS -2. Lancet 1988;2(8607):349-60. Abstract

Iversen P et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group study number 6. J Urol 2004;172(5 Pt 1):1871-6. Abstract

Iversen P et al; Casodex Early Prostate Cancer Trialists’ Group. Is the efficacy of hormonal therapy affected by lymph node status? Data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology 2004;63(5):928-33. Abstract

Labrie F et al. Major impact of hormonal therapy in localized prostate cancer-death can already be an exception. J Steroid Biochem Mol Biol 2004;92(5):327-344. Abstract

Miyamoto H, Messing EM. Early versus late hormonal therapy for prostate cancer. Curr Urol Rep 2004;5(3):188-96. Abstract

Moul JW et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004;171(3):1141-7. Abstract

Peto R, Dalesio O. Breast and prostate cancer: 10-year survival gains in the hormonal adjuvant treatment trials. Eur J Cancer Suppl 2003;1(5):S101;Abstract 328.

Roach M 3rd et al. Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000;47(3):617-27. Abstract

Schellhammer PF, Davis JW. An evaluation of bicalutamide in the treatment of prostate cancer. Clin Prostate Cancer 2004;2(4):213-9. Abstract

Schroder FH et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: Results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study. J Urol 2004;172(3):923-7. Abstract

Sciarra A et al. Antiandrogen monotherapy: Recommendations for the treatment of prostate cancer. Urol Int 2004;72(2):91-8. Abstract

Walsh PC et al. A structured debate: Immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol 2001;166(2):508-15. Abstract

Wirth MP et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004;172(5 Pt 1):1865-70. Abstract